SCRIBE THERAPEUTICS

scribe-therapeutics-logo

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to ground... breaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

#SimilarOrganizations #People #Financial #Event #Website #More

SCRIBE THERAPEUTICS

Social Links:

Industry:
Biotechnology Life Science Therapeutics

Founded:
2017-01-01

Address:
Alameda, California, United States

Country:
United States

Website Url:
http://www.scribetx.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
120 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Google Apps For Business


Similar Organizations

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

nutcracker-therapeutics-logo

Nutcracker Therapeutics

Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.

scout-bio-logo

Scout Bio

Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.


Current Advisors List

carl-l-gordon_image

Carl L. Gordon Board of Director @ Scribe Therapeutics
Board_member
2021-01-01

david-f-savage_image

David F. Savage Scientific Advisor @ Scribe Therapeutics
Advisor

behzad-aghazadeh_image

Behzad Aghazadeh Board of Director @ Scribe Therapeutics
Board_member
2021-01-01

Current Employees Featured

david-f-savage_image

David F. Savage
David F. Savage Co-Founder @ Scribe Therapeutics
Co-Founder

david-parrot_image

David Parrot
David Parrot CFO @ Scribe Therapeutics
CFO
2022-03-01

brett-staahl_image

Brett Staahl
Brett Staahl Co-Founder and VP of Platform @ Scribe Therapeutics
Co-Founder and VP of Platform

george-manning_image

George Manning
George Manning Controller @ Scribe Therapeutics
Controller
2021-08-01

jennifer-doudna_image

Jennifer Doudna
Jennifer Doudna Co-Founder @ Scribe Therapeutics
Co-Founder

benjamin-oakes_image

Benjamin Oakes
Benjamin Oakes Co-Founder, President & CEO @ Scribe Therapeutics
Co-Founder, President & CEO

Founder


benjamin-oakes_image

Benjamin Oakes

brett-staahl_image

Brett Staahl

david-f-savage_image

David F. Savage

jennifer-doudna_image

Jennifer Doudna

Investors List

wellington-management_image

Wellington Management

Wellington Management investment in Series B - Scribe Therapeutics

t-rowe-price_image

T. Rowe Price

T. Rowe Price investment in Series B - Scribe Therapeutics

avoro-ventures_image

Avoro Ventures

Avoro Ventures investment in Series B - Scribe Therapeutics

andreessen-horowitz_image

Andreessen Horowitz

Andreessen Horowitz investment in Series B - Scribe Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series B - Scribe Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Scribe Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Scribe Therapeutics

avoro-capital-advisors_image

Avoro Capital Advisors

Avoro Capital Advisors investment in Series B - Scribe Therapeutics

menlo-ventures_image

Menlo Ventures

Menlo Ventures investment in Series B - Scribe Therapeutics

andreessen-horowitz_image

Andreessen Horowitz

Andreessen Horowitz investment in Series A - Scribe Therapeutics

Official Site Inspections

http://www.scribetx.com

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 99.83.190.102
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Scribe Therapeutics"

Scribe → About - scribetx.com

Scribe is rewriting medicine with molecular engineering. Jennifer Doudna is the Li Ka Shing Chancellor's Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley, as …See details»

Scribe Therapeutics - Crunchbase Company Profile

Contact Email [email protected] Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s …See details»

Scribe Therapeutics - LinkedIn

Jun 16, 2020 Scribe Therapeutics | 12,826 followers on LinkedIn. CRISPR by Design™ | Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.See details»

Scribe Therapeutics - Overview, News & Similar companies

Mar 14, 2024 www.scribetx.com. Revenue $6 Million. Industry Manufacturing General Manufacturing . Most Recent Scoops. Apr 23 2024. Open Position . Mar 15 2024. Open …See details»

Scribe Therapeutics Presents Data Demonstrating Highly Potent …

May 10, 2024 Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-EdSee details»

Scribe Therapeutics - workinbiotech.com

Scribe Therapeutics is engineering new therapeutics using CRISPR. The underlying causes of many genetic diseases can be treated through gene editing. Scribe is focusing on in vivo …See details»

Company: Scribe Therapeutics - CRISPR Medicine

More than 100 companies to follow in 2023 working with a gene editing tool like CRISPR, TALEN, ZFN, Prime Editor, Base Editor, MegaNuclease...See details»

Scribe

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self …See details»

Scribe Therapeutics (Scribe Therapeutics) - 药物管线_专利_临床试 …

ALAMEDA, Calif.--( BUSINESS WIRE )--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that …See details»

Scribe Therapeutics - Golden

Scribe develops gene-editing therapies based on CRISPR-CasX, an RNA-guided genome-editing platform. The company was founded in 2018 by Jennifer Doudna, Benjamin Oakes, David F. …See details»

Scribe Therapeutics Raises $100M Series B Financing to Further

Mar 31, 2021 To learn more about Scribe’s technology, industry partnership opportunities, and careers, visit www.scribetx.com. About Scribe Therapeutics. Scribe Therapeutics is a …See details»

Scribe → Platform

Discovery. Naturally occurring CRISPR systems have revolutionized genetic medicine since 2012, when their potential for gene editing was unlocked in the lab of our co-founder, Nobel Laureate …See details»

Scribe Therapeutics Unveils Fully Integrated Platform for …

Oct 6, 2020 To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com. Contacts. Thermal for Scribe Therapeutics Kaustuva Das …See details»

Scribe → Scribe Therapeutics Expands Collaboration With Biogen …

May 2, 2022 The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the …See details»

Chief Executive Officer at Scribe Therapeutics - ZoomInfo

Aug 10, 2024 About; Company; Experience; Org Chart; News & Media; Similar Profiles; About Benjamin Oakes Benjamin L. Oakes, PhD, is Co-founder, President, and Chief Executive …See details»

Scribe Achieves Milestone for In Vivo Program in Collaboration …

Apr 28, 2025 Success milestone reached in Scribe and Prevail’s ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe’s …See details»

More like this - scribetx.com

May 16, 2023See details»

Scribe Therapeutics Achieves Milestone for In Vivo Program in ...

Jan 13, 2025 Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail …See details»

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome …

May 5, 2025 Organization: PRI Release Summary Scribe to highlight in vivo CRISPR-based genome editing data for Duchenne Muscular Dystrophy at ASGCT 2025, plus joint …See details»

Scribe → Scribe Therapeutics Presents Data on its X-Editing ...

May 19, 2023. Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingSee details»

linkstock.net © 2022. All rights reserved